nach oben

Cardiovascular Toxicology

Erschienen in:

02.07.2018

Beneficial Effect of Silymarin in Pressure Overload Induced Experimental Cardiac Hypertrophy

verfasst von: Basant Sharma, Udit Chaube, Bhoomika M. Patel

Erschienen in: Cardiovascular Toxicology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

The present investigation was undertaken to study the effect of silymarin on cardiac hypertrophy induced by partial abdominal aortic constriction (PAAC) in Wistar rats. Silymarin was administered for 9 weeks at the end of which we evaluated hypertrophic, hemodynamic, non-specific cardiac markers, oxidative stress parameters, and determined mitochondrial DNA concentration. Hypertrophic control animals exhibited cardiac hypertrophy, altered hemodynamics, oxidative stress, and decreased mitochondrial DNA (mtDNA) concentration. Treatment with silymarin prevented cardiac hypertrophy, improved hemodynamic functions, prevented oxidative stress and increased mitochondrial DNA concentration. Docking studies revealed that silymarin produces maximum docking score with mitogen-activated protein kinases (MAPK) p38 as compared to other relevant proteins docked. Moreover, PAAC-control rats exhibited significantly increased expression of MAPK p38β mRNA levels which were significantly decreased by the treatment of silymarin. Our data suggest that silymarin produces beneficial effects on cardiac hypertrophy which are likely to be mediated through inhibition of MAPK p38β.

Anan, R., Nakagawa, M., Miyata, M., Higuchi, I., Nakao, S., Suehara, M., et al. (1995). Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation, 91(4), 955–961.CrossRef

Andrews, C., Ho, P., Dillmann, W., Glembotski, C., & McDonoughc, P. (2003). The MKK6–p38 MAPK pathway prolongs the cardiac contractile calcium transient, downregulates SERCA2, and activates NF-AT. Cardiovascular Research, 59, 46–56.CrossRef

Anton, R., Bauer, S. M., Keck, P., & Laufer, P. (2014). A p38 Substrate-Specific MK2-EGFP translocation assay for identification and validation of new p38 inhibitors in living cells: A comprising alternative for acquisition of cellular p38 inhibition. PLoS ONE, 9, e95641.CrossRef

Barja, G., & Herrero, A. (2000). Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heat and brain of mammals. The FASEB Journal, 14, 312–318.CrossRef

Bernardo, B. C., Weeks, K. L., Pretorius, L., & McMullen Jr. (2010). Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacology & Therapeutics, 128, 191–227.CrossRef

Borah, A., Paul, R., Choudhury, S., Choudhury, A., Bhuyan, B., Talukdar, D., A., et al (2013). Neuroprotective potential of silymarin against CNS disorders: Insight into the pathways and molecular mechanisms of action. CNS Neuroscience Therapeutics, 19, 847–853.CrossRef

Buckley, D. I., Fu, R., Freeman, M., Rogers, K., & Helfand, M. (2009). C-reactive protein as a risk factor for coronary heart disease: A systematic review and meta-analyses for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 151, 483–495.CrossRef

Bugger, H., & Abel, E. D. (2010). Mitochondria in the diabetic heart. Cardiovascular Research, 88, 229–240.CrossRef

Chen, P. N., Hsieh, Y. S., Chiou, H. L., & Chu, S. C. (2005). Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chemico-Biological Interactions, 156(2–3), 141–150.CrossRef

10.

Dai, D. F., Johnson, S. C., Villarin, J. J., Chin, M. T., Nieves-Cintron, M., Chen, T., et al. (2011). Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circulation Research, 108, 837–846.CrossRef

11.

Dhalla, N. S., Temsah, R. M., & Netticadan, T. (2000). Role of oxidative stress in cardiovascular diseases. Journal of Hypertension, 18, 655–673.CrossRef

12.

Dickhout, J. G., Carlisle, R. E., & Austin, R. C. (2011). Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: Endoplasmic reticulum stress as a mediator of pathogenesis. Circulation Research, 108(5), 629–642.CrossRef

13.

Elkamhawy, A., Lee, J., Park, B. G., Park, I., Pae, A. N., & Roh, E. J. (2014). Novel quinazoline-urea analogues as modulators for Aβ-induced mitochondrial dysfunction: Design, synthesis, and molecular docking study. European Journal of Medicinal Chemistry, 84, 466–475.CrossRef

14.

Frey, N., & Olson, E. N. (2003). Cardiac hypertrophy: The good, the bad, and the ugly. Annual Review of Physiology, 65, 45–79.CrossRef

15.

Gabrielová, E., Zholobenko, A. V., Bartošíková, L., Nečas, J., & Modriansky, M. (2015). Silymarin constituent 2,3-dehydrosilybin triggers reserpine-sensitive positive inotropic effect in perfused rat heart. PLoS ONE, 10(9), e0139208.CrossRef

16.

Gharagozloo, M., Jafari, S., Esmaeil, N., Javid, E. N., Bagherpour, B., & Rezaei, A. (2013). Immunosuppressive effect of silymarin on mitogen-activated protein kinase signalling pathway: The impact on T cell proliferation and cytokine production. Basic & Clinical Pharmacology & Toxicology, 113, 209–214.CrossRef

17.

Goyal, B. R., & Mehta, A. A. (2012). Beneficial role of spironolactone, telmisartan and their combination on isoproterenol induced cardiac hypertrophy. Acta Cardiologica, 67, 203–211.CrossRef

18.

Goyal, B. R., & Mehta, A. A. (2013). Diabetic cardiomyopathy: Pathophysiological mechanisms and cardiac dysfunction. Human & Experimental Toxicology, 32, 571–590.CrossRef

19.

Goyal, B. R., Mesariya, P., Goyal, R. K., & Mehta, A. A. (2008). Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats. Molecular and Cellular Biochemistry, 314, 123–131.CrossRef

20.

Goyal, B. R., Parmar, K., Goyal, R. K., & Mehta, A. A. (2011). Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type-2 diabetic rats. Pharmacological Reports, 63, 956–966.CrossRef

21.

Goyal, B. R., Patel, M. M., & Bhadada, S. V. (2011). Comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril on diabetes induced cardiovascular complications in type 1 diabetes in rats. International Journal of Diabetes and Metabolism, 19, 11–18.

22.

Goyal, B. R., Solanki, N., Goyal, R. K., & Mehta, A. A. (2009). Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes. Journal of Cardiovascular Pharmacology, 54, 502–509.CrossRef

23.

Hakan, A. Y., Arsava, M., & Okay, S. (2002). Creatine kinase-MB elevation after stroke is not cardiac in origin. Stroke 33, 286–290.

24.

Horton, J. W., Tan, J., White, J., & Maass, D. (2007). Burn injury decreases myocardial Na- K-ATPase activity: Role of PKC inhibition. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 293, R1684–R1692.CrossRef

25.

Huang, Q., Wu, L. J., Tashiro, S., Onodera, S., Li, L. H., & Ikejima, T. (2005). Silymarin augments human cervical cancer HeLa cell apoptosis via P38/JNK MAPK pathways in serum-free medium. Journal of Asian Natural Products Research, 7(5), 701–709.CrossRef

26.

Karamanlidis, G., Bautista-Hernandez, V., Fynn-Thompson, F., Del Nido, P., & Tian, R. (2011). Impaired mitochondrial biogenesis precedes heart failure in right ventricular hypertrophy in congenital heart disease. Circulation: Heart Failure, 4, 707–713.

27.

Katholi, R. E., & Couri, D. M. (2011). Left ventricular hypertrophy: Major risk factor in patients with hypertension: Update and practical clinical applications. International Journal of Hypertension. https://doi.org/10.4061/2011/495349 CrossRefPubMedPubMedCentral

28.

Kumphune, S., Chattipakorn, S., & Chattipakorn, N. (2012). Role of p38 inhibition in cardiac ischemia/reperfusion injury. European Journal of Clinical Pharmacology, 68, 513–524.CrossRef

29.

Lee, J. K., & Kim, N. J. (2017). Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer’s disease. Molecules, 22(8), E1287.CrossRef

30.

Li, P. C., Chiu, Y. W., Lin, M. Y., Day, H. C., Hwang, G. Y., Pai, P., Tsai, F. J., Tsai, C. H., Kuo, Y. C., Chang, H. C., Liu, J. Y., & Huang, C. Y. (2012). Herbal supplement ameliorates cardiac hypertrophy in rats with -induced liver cirrhosis. Evidence-Based Complementary and Alternative Medicine. https://doi.org/10.1155/2012/139045 CrossRefPubMedPubMedCentral

31.

Molkentin, J. D., & Dorn, G. W. (2001). Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annual Review of Physiology, 63, 391–426.CrossRef

32.

Patel, B. M. (2018). Sodium butyrate controls cardiac hypertrophy in experimental models of rats. Cardiovascular Toxicology, 18(1), 1–8.CrossRef

33.

Patel, B. M., Agarwal, S. S., & Bhadada, S. V. (2012). Perindopril protects against streptozotocin induced hyperglycemic myocardial damage/alterations. Human & Experimental Toxicology, 31(11), 1138–1149.CrossRef

34.

Patel, B. M., & Desai, V. J. (2014). Beneficial role of tamoxifen in experimentally induced cardiac hypertrophy. Pharmacological Reports, 66, 264–272.CrossRef

35.

Patel, B. M., & Bhadada, S. V. (2014). Type 2 diabetes induced cardiovascular complications: Comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril. Clinical and Experimental Hypertension, 36, 340–347.CrossRef

36.

Patel, B. M., Kakadiya, J., Goyal, R. K., & Mehta, A. A. (2013). Effect of spironolactone on cardiovascular complications associated with type-2 diabetes in rats. Experimental and Clinical Endocrinology, 121, 441–447.CrossRef

37.

Patel, B. M., Mehta, A. A. (2013). The choice of anti-hypertensive agents in diabetic subjects. Diabetes and Vascular Disease Research, 10, 385–396.CrossRef

38.

Patel, B. M., & Mehta, A. A. (2012). Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. European Journal of Pharmacology, 697, 1–12.CrossRef

39.

Patel, B. M., Raghunathan, S., & Porwal, U. (2014). Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus. European Journal of Pharmacology, 728, 128–134.CrossRef

40.

Peppers, V., Ramos, G., Manias, E., Koroboki, E., Rokas, S., & Zakopoulos, N. (2008). Correlation between myocardial enzyme serum levels and markers of inflammation with severity of coronary artery disease and Gensini score: A hospital-based prospective study in Greek patients. Clinical Interventions in Aging, 3, 699–710.CrossRef

41.

Post-White, J., Ladas, E. J., & Kelly, K. M. (2007). Advances in the use of milk thistle (Silybum marianum). Integrative Cancer Therapies, 6, 104–109.CrossRef

42.

Prockop, D. J., & Udenfriend, S. (1960). A specific method for the analysis of hydroxyproline in tissues and urine. Analytical Biochemistry, 1, 228–239.CrossRef

43.

Raghunathan, S., & Patel, B. M. (2013). Therapeutic implications of small interfering RNA in cardiovascular diseases. Fundamental and Clinical Pharmacology, 27, 1–20.CrossRef

44.

Rao, P. R., & Viswanath, R. K. (2007). Cardioprotective activity of silymarin in ischemia-reperfusion-induced myocardial infarction in albino rats. Experimental & Clinical Cardiology, 12, 179–187.

45.

Rayabarapu, N., & Patel, B. M. (2014). Beneficial role of tamoxifen in isoproterenol induced myocardial infarction. Canadian Journal of Physiology and Pharmacology, 92, 849–857.CrossRef

46.

Rosca, M. G., Tandler, B., & Hoppel, C. L. (2013). Mitochondria in cardiac hypertrophy and heart failure. Journal of Molecular and Cellular Cardiology, 55, 31–41.CrossRef

47.

Rose, B. A., Force, T., & Wang, Y. (2010). Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiological Reviews, 90, 1507–1546.CrossRef

48.

Sakottova, N., Vecera, R., Urbenek, K., Vana, P., Walterova, D., & Cvak, L. (2003). Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets. Pharmacological Research, 47, 17–26.CrossRef

49.

Sanz-Moreno, V., & Crespo, P. (2003). p38 mitogen-activated protein kinases: Their role in carcinogenesis. Revista de oncología, 5, 320–330.

50.

Thakare, V. N., Aswar, M. K., Kulkarni, Y. P., Patil, R. R., & Patel, B. M. (2017). Silymarin ameliorates experimentally induced depressive like behavior in rats: Involvement of hippocampal BDNF signaling, inflammatory cytokines and oxidative stress response. Physiology & Behavior, 179, 401–410.CrossRef

51.

Thakare, V. N., Dhakane, V. D., & Patel, B. M. (2016). Potential antidepressant-like activity of silymarin in the acute restraint stress in mice: Modulation of corticosterone and oxidative stress response in cerebral cortex and hippocampus. Pharmacological Reports, 68, 1020–1027.CrossRef

52.

Thakare, V. N., Patil, R. R., Oswal, R. J., Dhakane, V. D., Aswar, M. K., & Patel, B. M. (2018). Therapeutic potential of silymarin in chronic unpredictable mild stress induced depressive-like behavior in mice. Journal of Psychopharmacology, 32, 223–235.CrossRef

53.

Tsimaratos, M., Coste, T. C., Djemli-Shipkolye, A., Daniel, L., Shipkolye, F., Vague, P., & Raccah, D. (2001). Evidence of time-dependent changes in renal medullary Na,K-ATPase activity and expression in diabetic rats. Cellular Molecular Biology (Noisy-le-grand), 47, 239–245.

54.

Tuorkey, M. J., El-Desouki, N. I., & Kamel, R. A. (2015). Cytoprotective effect of Silymarin against diabetes-induced cardiomyocyte apoptosis in diabetic rats. Biomedical and Environmental Sciences, 28(1), 36–43.PubMed

55.

Wang, Y., Huang, S., Sah, V. P., Ross, J., Brown, J. H., Han, J., & Chien, K. R. (1998). Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. Journal of Biological Chemistry, 273, 2161–2168.CrossRef

56.

Wu, J. H., Hagaman, J., Kim, S., Reddick, R. L., & Maeda, N. (2002). Aortic constriction exacerbates atherosclerosis and induces cardiac dysfunction in mice lacking apolipoprotein E. Arteriosclerosis, Thrombosis, and Vascular Biology, 22(3), 469–475.CrossRef

57.

Zhang, S., Weinheimer, C., Courtois, M., Kovacs, A., Zhang, C. E., Cheng, A. M., Wang, Y., & Muslin, A. J. (2003). The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. Journal of Clinical Investigation, 111, 833–841.CrossRef

58.

Zholobenko, A., & Modriansky, M. (2014). Silymarin and its constituents in cardiac preconditioning. Fitoterapia, 97, 122–132.CrossRef

59.

Zhou, B., Wu, L. J., Tashiro, S., Onodera, S., Uchiumi, F., & Ikejima, T. (2007). Activation of extracellular signal-regulated kinase during silibinin-protected, isoproterenol-induced apoptosis in rat cardiac myocytes is tyrosine kinase pathway-mediated and protein kinase C-dependent. Acta Pharmacologica Sinica, 28(6), 803–810.CrossRef

Titel: Beneficial Effect of Silymarin in Pressure Overload Induced Experimental Cardiac Hypertrophy
verfasst von: Basant Sharma
Udit Chaube
Bhoomika M. Patel
Publikationsdatum: 02.07.2018
Verlag: Springer US
Erschienen in: Cardiovascular Toxicology / Ausgabe 1/2019
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-018-9470-2

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Nano-medicine and Vascular Endothelial Dysfunction: Options and Delivery Strategies

Increased Plasma Nitrite and von Willebrand Factor Indicates Early Diagnosis of Vascular Diseases in Chemotherapy Treated Cancer Patients

Severe Cardiomyopathy Due to Arthroprosthetic Cobaltism: Report of Two Cases with Different Outcomes

Refractory Arrhythmias in a Young Patient Poisoned by Imipramine

Endothelial Cells: From Dysfunction Mechanism to Pharmacological Effect in Cardiovascular Disease

Anti-fibrotic Actions of Roselle Extract in Rat Model of Myocardial Infarction